SEPTEMBER BDI-40 DOWN 4.8%; ASX200 DOWN 6.7%
October 8th 2011 06:44
Biotech Daily
Monday October 3, 2011
Daily news on ASX-listed biotechnology companies
Monday October 3, 2011
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH DAILY’S TOP 40 INDEX
BDI-40 LEADS OVER 1, 2, 5 YEARS
COCHLEAR DOWN 39% ALLIED DOWN 38%; SUNSHINE HEART UP 27%
Despite a six-month downward trend, the Biotech Daily Top 40 Index (BDI-40) has remained well ahead of the S&P ASX200 for the year, for two years and over five years.
The BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) first surpassed the ASX200 numerically in November 2009 and apart from two months (August and September 2010; see charts below) has held a clear lead over the benchmark index.
In the 12 months to October 1, 2011, the BDI-40 climbed 38.0 percent compared to the ASX200 falling 12.5 percent. For the two year period, the BDI-40 was up 46.9 percent with the ASX200 down 15.5 percent and over five years, the BDI-40 was up 72.9 percent, while the ASX200 fell 22.2 percent.
In September, the BDI-40 fell 4.8 percent compared to the ASX200 losing 6.7 percent.
The three Big Caps fell 3.3 percent for the month, dragged down by Cochlear’s Nucleus Five recall (BD: Sep 12, 2011) losing 38.7 percent of its market capitalization to $2,639 million and despite a 5.0 percent rise by CSL to $15,582 million and a 3.5 percent improvement by Resmed to $4,575 million.
The biggest Top 40 fall was Acrux’s $106 million loss of market capitalization, down 16.5 percent to $533 million, attributed by the company to “short selling” (BD: Sep 29, 2011). Surprisingly, nine of the Top 40 companies were up, unsurprisingly 28 fell and three looked good by not moving at all.
By percentage, Allied Health fell the furthest, down 37.9 percent to $29 million on a 2.8 cent a share placement, followed by LBT down 33.3 percent to $4 million on no news about Biomérieux royalties, Patrys (27.8%), Impedimed (23.3%), Pharmaxis (21.7%), Circadian (21.4%), Compumedics (20%), Uscom (20%) and Biota (18.9%).
The best was Sunshine Heart, despite a poor PR campaign to sell its positive pilot study results (BD: Sep 22, 2011) up 26.7 percent to $57 million, followed by Antisense (12.5%), Viralytics (7.5%), Heartware (6.8%), Alchemia (6.15%), Clinuvel (4.5%), Universal Biosensors (2.8%) and Psivida (1.1%).
BDI-40 v ASX200 Jun 30, 2006 To Sep 30, 2011
BDI-40 v ASX200 Sep 30, 2010 To Sep 30, 2011
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 15 |
| Vote |
Add To: 
subscribe to this blog